Clinical Trials Directory

Trials / Completed

CompletedNCT02222376

Effect of Topic Pirfenidone in Diabetic Ulcers

Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Pirfenidone is a synthetic molecule, which acts as a potent modulator of the effect of various cytokines (TNF-α, transforming growth factor-β, platelet derived growth factor and vascular endothelial growth factor, among others) that possesses anti-inflammatory and anti-fibrinolytic properties. The aim of this study is to compare the effect of topic treatment with pirfenidone compared to conventional treatment in chronic diabetic foot ulcers. The hypothesis is that treatment with topic pirfenidone in chronic diabetic foot ulcers (Wagner 1 to 2) reduces the ulcer size and shortens the healing time compared to conventional treatment. This is a randomized, controlled and crossover study. Patients will be randomly assigned to conventional treatment or topic pirfenidone for eight weeks. At the end of this period they will change groups. Each week ulcers will be for size, depth, length and evidence of infection. The ulcers will have proper debridement in the conventional treatment group and debridement plus topical pirfenidone application in the pirfenidone group. Subjects will be instructed to do daily ulcer cleansing and for those in the topical pirfenidone group, in addition to cleansing they will be instructed to apply the gel twice a day.

Conditions

Interventions

TypeNameDescription
DRUGPirfenidoneTwice a day topical application
PROCEDUREDebridementWeekly ulcer debridement

Timeline

Start date
2013-10-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2014-08-21
Last updated
2016-02-15

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02222376. Inclusion in this directory is not an endorsement.